SGMO alert back on 9/10 Monday has broken out of a 1 year cup and handle on the biggest volume for this stock in 7 months. The break out occurred at $6.16. First target $6.70, then $1 more until mid $9 range. The price has been up 6 days in a row and is overbought, and support is at the break out price.
Sent: 9/10/2012 11:47:48 A.M. Mountain Daylight Time
Subj: bio
12:31 SGMO Sangamo BioSci announces presentation of clinical data from ZFP Therapeutics for HIV/AIDS at ICAAC 2012: findings demonstrate immune reconstitution and potential success of "functional cure" in HIV-infected individuals (5.96 +0.12)
Co announced that data from its Phase 1 clinical programs to develop SB-728-T, a novel therapeutic approach designed to generate a "functional cure" for HIV/AIDS, were presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The meeting is being held in San Francisco from September 9-12, 2012. In an oral presentation made on Monday, September 10th, 2012 at ICAAC, data were presented from all dosing cohorts of Sangamo's Phase 1 dose-escalation study (SB-728-902) in subjects on highly active antiretroviral therapy (HAART). The data demonstrate that SB-728-T infusion in HIV-infected subjects is well-tolerated, and results in significant and sustained increases in CD4+ T-cells above baseline throughout the year-long period reported in the study. Statistically significant improvement in CD4 counts were observed even at 12 months post infusion (p<0.038). In particular, CD4 counts improved to greater than 500 cells/mm3 in five of nine subjects in the study at one year post-treatment, which is the usual T-cell count threshold for initiation of HAART in HIV-infected subjects.
Market Data 
Markets 
AI
